Inst. Holders
1 funds
RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.
$0.5000 ▲ +0.00%
Prev close $0.500012-mo target$17.50 (+3400.0%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on RVPH right now — valuation, ownership and activity at a glance.
Inst. Value
$412.00
SEC Reports
6
Press Releases
3
Price chart 30d -7.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 17, 2026 earnings_calendar
Aug 12, 2026 SEC RVPH Q2 2026 Earnings Scheduled — 2026-08-17
Reviva Pharmaceuticals reported Q2 2026 net loss of $2.4M ($0.19/share), narrower than the $6.1M loss in Q2 2025, but EP
PRESS-RELEASE — Impact 4/10
Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Holdings, Inc. from listing and registration, effective
25-NSE — Impact 7/10
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/sh
PRESS-RELEASE — Impact 7/10
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2
Impact 6/10
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompa
Impact 6/10
Mar 18, 2026 Insider
Bhat Laxminarayan was granted 109,150 shares
President and CEO
Mar 18, 2026 Insider
Prabhu Narayan was granted 40,925 shares
Chief Financial Officer
Analyst ratings buy % -10.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 8, 2026 | Maxim Group | DOWNGRADE | Hold | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% |
Price targets
Where 2 covering analysts think RVPH trades over the next 12 months.
$17.50 +3400.0% upside Strong Buy
Current$0.5000 Low$5.00 Median$17.50 High$30.00 2 analysts
$5.00$30.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 3 bearish, 0 mixed, 3 neutral · avg impact 6.0/10.Plus 3 press releases.
NEUTRALPRESS-RELEASE4/10
Reviva Pharmaceuticals reported Q2 2026 net loss of $2.4M ($0.19/share), narrower than the $6.1M los
Aug 12, 2026
BEARISH25-NSE7/10
Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Holdings, Inc. from listing and regi
Jul 10, 2026
BEARISHPRESS-RELEASE7/10
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago
May 13, 2026
BEARISH8-K8/10
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the
May 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 17, 2026
earnings_calendar
RVPH Q2 2026 Earnings Scheduled — 2026-08-17
Aug 12, 2026
earnings
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and co
May 18, 2026
earnings_calendar
RVPH Q1 2026 Earnings Scheduled — 2026-05-18
May 13, 2026
earnings
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and
May 13, 2026
earnings_calendar
RVPH Q1 2026 Earnings Scheduled — 2026-05-13
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.18 | $-0.18–$-0.18 | 85.0% | +50.0% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.16 | $-0.16–$-0.16 | 96.9% | +60.0% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-0.85 | $-0.85–$-0.85 | 84.5% | +46.9% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.85 | $-0.85–$-0.85 | 0.0% | +55.3% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.180 | — |
| 7d ago | $-0.360 | +0.180 |
| 30d ago | $-0.360 | +0.180 |
| 60d ago | $-0.360 | +0.180 |
| 90d ago | $-0.230 | +0.050 |
Institutional ownership
Which big funds own RVPH (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $412.00 total value (625 shares) as of 2026-Q2. Top holders: TD.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| TD Waterhouse Canada Inc. | 625 | $412.00 | 100.0% | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 3 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Bhat Laxminarayan | President and CEO | AWARD | 109,150 | — | — |
| Mar 18, 2026 | Prabhu Narayan | Chief Financial Officer | AWARD | 40,925 | — | — |
| Mar 18, 2026 | Bhat Laxminarayan | President and CEO | AWARD | 40,925 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RVPH.
Shares short
405,082
Settlement Sep 15, 2026
Change vs prior
+1.2%
Semi-monthly cycle
Days to cover
7.5
At avg daily volume
All RVPH filing & press-release reports (9)
- PRESS-RELEASE reportAug 12, 2026
- 25-NSE reportJul 10, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 13, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 18, 2026
- 8-K reportMar 5, 2026